PSY FPX 6110 Assessment 1 Annotated Bibliography-Psychedelic Therapy Studies

PSY FPX 6110 Assessment 1 Annotated Bibliography-Psychedelic Therapy Studies

Student Name

Capella University

PSY FPX 6110 Learning Theories in Psychology

Prof. Name

Date

Annotated Bibliography

Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019). 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) utilized in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse, 45(2), 161–169. https://doi.org/10.1080/00952990.2018.1545024

Davis, So, Lancelotta, Barsuglia, and Griffiths (2019) explored the use of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a communal environment, revealing unintended alleviations in depression and anxiety. The study assessed self-reported levels of depression and anxiety among individuals consuming 5-MeO-DMT in a group context characterized by structured dosing, procedures, and support systems. The results indicated that post-usage of 5-MeO-DMT, participants reported improvements in symptoms of depression and anxiety. These enhancements were linked to heightened spiritual significance and personal meaning attributed to the experience.

Duerler, P., Schilbach, L., Stämpfli, P., Vollenweider, F. X., & Preller, K. H. (2020). LSD-induced increases in social adaptation to opinions congruent with one’s own are associated with stimulation of serotonin receptors. Scientific Reports, 10(1), 12181. https://doi.org/10.1038/s41598-020-68899-y

Duerler et al. (2020) examined the influence of LSD on social adaptation to opinions aligned with one’s own, elucidating the role of serotonin receptors in social influence processing. In a double-blind random crossover study involving 24 volunteers, participants received either a placebo, LSD (100 micrograms), or a 5HT2A receptor antagonist plus LSD (100 micrograms) over three sessions. The findings revealed that LSD facilitated social adaptation, particularly when individuals encountered opinions congruent with their own. This effect correlated with increased activity in the ventral medial prefrontal cortex during social feedback processing, providing insights into the neuropharmacological mechanisms underlying social cognitive behavior.

Forstmann, M., Yudkin, D. A., Prosser, A. M., Heller, S. M., & Crockett, M. J. (2020). Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proceedings of the National Academy of Sciences, 117(5), 2338–2346. https://doi.org/10.1073/pnas.1918477117

Forstmann et al. (2020) investigated the mediating roles of transformative experiences and social connectedness in the mood-enhancing effects of psilocybin and other psychedelics in naturalistic settings. Over a three-year span, the study involving 1,225 participants across multiple mass gatherings utilized field studies and questionnaire assessments. The findings suggested that recent psychedelic use was linked to heightened transformative experiences and social connectedness, subsequently mediating improvements in positive mood. This study underscores the potential of psychedelics to induce personal transformation and enhance social cohesion in naturalistic settings, conducted with ethical approval from the Oxford Central Research Ethics Committee.

PSY FPX 6110 Assessment 1 Annotated Bibliography-Psychedelic Therapy Studies

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology (Oxford), 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513

Griffiths et al. (2016) investigated the effects of psilocybin on depression and anxiety symptoms in cancer patients through a randomized double-blind trial. Involving 51 patients with life-threatening diagnoses, the study administered either a low or high dose of psilocybin in a cross-over design. Significant reductions in depression and anxiety, coupled with increased life meaning and optimism, were observed following high-dose psilocybin administration. These effects were sustained at the 6-month follow-up, indicating the therapeutic potential of psilocybin in alleviating psychological distress in cancer patients.

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., Tzarfaty, K., … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3

PSY FPX 6110 Assessment 1 Annotated Bibliography-Psychedelic Therapy Studies

Mitchell et al. (2021) conducted a phase 3 trial to evaluate the efficacy and safety of MDMA-assisted therapy for severe PTSD. Ninety participants were randomized to receive either MDMA therapy or a placebo, alongside preparatory and integrative sessions. Significant reductions in PTSD symptoms were noted in the MDMA group compared to the placebo, with some patients achieving remission after just one or two sessions. This study underscores the promising therapeutic potential of MDMA-assisted therapy in individuals with severe PTSD, warranting further clinical evaluation.